Ken Cacciatore
Stock Analyst at TD Cowen
(0.27)
# 4,103
Out of 4,832 analysts
14
Total ratings
25%
Success rate
-30.5%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $13.60 | +267.65% | 2 | Aug 9, 2023 | |
BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $4.56 | - | 1 | Jun 16, 2023 | |
TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $13.71 | +45.88% | 4 | May 16, 2023 | |
SCPH scPharmaceuticals | Initiates: Outperform | $25 | $2.24 | +1,016.07% | 1 | Dec 1, 2022 | |
BLCO Bausch + Lomb | Initiates: Outperform | $35 | $11.55 | +203.03% | 1 | May 11, 2022 | |
MOLN Molecular Partners AG | Initiates: Outperform | $50 | $3.97 | +1,159.45% | 1 | Jul 13, 2021 | |
TARA Protara Therapeutics | Initiates: Outperform | $50 | $3.13 | +1,497.44% | 1 | Oct 19, 2020 | |
BHVN Biohaven | Initiates: Outperform | $45 | $19.66 | +128.89% | 1 | Apr 17, 2020 | |
AMRN Amarin Corporation | Initiates: Outperform | $460 | $10.15 | +4,432.02% | 1 | Mar 2, 2020 | |
OPTN OptiNose | Initiates: Outperform | $375 | $9.48 | +3,855.70% | 1 | Dec 18, 2019 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $13.60
Upside: +267.65%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.56
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $13.71
Upside: +45.88%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $2.24
Upside: +1,016.07%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $11.55
Upside: +203.03%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $3.97
Upside: +1,159.45%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $3.13
Upside: +1,497.44%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $19.66
Upside: +128.89%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $10.15
Upside: +4,432.02%
OptiNose
Dec 18, 2019
Initiates: Outperform
Price Target: $375
Current: $9.48
Upside: +3,855.70%